Suomi - suomi - Fimea (Suomen lääkevirasto)

boehringer ingelheim vetmedica gmbh - pimobendan - purutabletti - 2.5 mg - pimobendaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

boehringer ingelheim vetmedica gmbh - pimobendan - purutabletti - 5 mg - pimobendaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

boehringer ingelheim vetmedica gmbh - pimobendan - purutabletti - 10 mg - pimobendaani

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).

Euroopan unioni - suomi - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Euroopan unioni - suomi - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - kaikki muut terapeuttiset tuotteet - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.